
|Articles|September 25, 2014
- Gynecologic Cancers (Issue 1)
- Volume 1
- Issue 1
The Role of Molecular Testing in Gynecologic Cancers
Author(s)Maurie Markman, MD
Maurie Markman, MD, discusses the role of molecular testing in gynecologic cancers.
Advertisement
Maurie Markman, MD, senior vice president for Clinical Affairs and National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses the role of molecular testing in gynecologic cancers.
View more about screening for ovarian cancer > >
Articles in this issue
over 11 years ago
Trabectedin as a Treatment Option for Patients with Ovarian Cancerover 11 years ago
Dream Team Aims To Change the Face of Ovarian Cancer Researchover 11 years ago
On The Horizon for Ovarian Cancer: Potentially Promising TreatmentsAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















